Detalles de la búsqueda
1.
Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma.
Cancer Sci
; 115(6): 2002-2011, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38498976
2.
Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma.
Ann Hematol
; 102(9): 2493-2504, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37341778
3.
Once Monthly Elotuzumab and Lenalidomide Plus Dexamethasone for Multiple Myeloma: A Multicenter Observation Study.
Acta Haematol
; 146(2): 125-136, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36538896
4.
Efficacy and safety of Wilms' tumor 1 helper peptide OCV-501 in elderly patients with acute myeloid leukemia: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial.
Cancer Immunol Immunother
; 71(6): 1419-1430, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-34677647
5.
HLA loci predisposing to immune TTP in Japanese: potential role of the shared ADAMTS13 peptide bound to different HLA-DR.
Blood
; 135(26): 2413-2419, 2020 06 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-32253422
6.
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 379(19): 1811-1822, 2018 11 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30403938
7.
Hypofibrinogenemia is associated with a high degree of risk in infectious diseases: a post-hoc analysis of post-marketing surveillance of patients with disseminated intravascular coagulation treated with thrombomodulin alfa.
Thromb J
; 19(1): 12, 2021 Feb 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-33632246
8.
Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM.
Cancer Sci
; 111(6): 2116-2122, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32297407
9.
Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment-free remission.
Cancer Sci
; 111(8): 2923-2934, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32614159
10.
Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma.
Ann Hematol
; 99(5): 1063-1072, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32248251
11.
Analysis of the association between resolution of disseminated intravascular coagulation (DIC) and treatment outcomes in post-marketing surveillance of thrombomodulin alpha for DIC with infectious disease and with hematological malignancy by organ failure.
Thromb J
; 18: 2, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32047363
12.
[Hematologic malignancies and health economics].
Rinsho Ketsueki
; 61(7): 725-733, 2020.
Artículo
en Japonés
| MEDLINE | ID: mdl-32759557
13.
Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma.
Ann Hematol
; 98(7): 1703-1711, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31049648
14.
Phase II Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Over 75 Years Old with Alternating Bortezomib/dexamethasone and Lenalidomide/dexamethasone: the MARBLE Trial.
Acta Med Okayama
; 73(6): 547-552, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31871340
15.
Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation.
Cancer Sci
; 109(1): 182-192, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29058817
16.
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.
Haematologica
; 103(12): 2088-2096, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30237262
17.
Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma.
Hematol Oncol
; 36(5): 792-800, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30176173
18.
Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pibased therapy in relapsed/refractory multiple myeloma.
Ann Hematol
; 102(9): 2505, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37432416
19.
Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan.
Cancer Sci
; 108(3): 461-468, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28092421
20.
Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Int J Clin Oncol
; 22(5): 972-979, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28550414